

8th Annual




BIOTECH · HEALHTECH · MEDTECH















10-11 MAY, 2022 | 133 HOUNDSDITCH | LONDON | UK

16-20 MAY, 2022 | VIRTUAL

Co-located:



EVENT AT A GLANCE

Tuesday-Wednesday 10-11 May	Wednesday-Friday 12-13 May	Monday-Friday 16-20 February
<div data-bbox="353 544 763 655">  BIOTECH · HEALTHTECH · MEDTECH </div> <div data-bbox="400 708 801 735"> 133 HOUNDSDITCH LONDON UK </div> <div data-bbox="304 775 828 871">    </div> <div data-bbox="380 938 819 965"> Physical Content & Physical Showcases </div> <div data-bbox="470 1002 730 1029"> Physical 1:1 Partnering </div>	<div data-bbox="1061 772 1270 895"> Virtual 1:1 Partnering Virtual Showcases </div>	<div data-bbox="1458 544 1874 655">  BIOTECH · HEALTHTECH · MEDTECH </div> <div data-bbox="1621 708 1736 735"> VIRTUAL </div> <div data-bbox="1406 775 1944 871">    </div> <div data-bbox="1509 938 1850 965"> Physical Content On-Demand </div> <div data-bbox="1574 1002 1792 1029"> Virtual Showcases </div> <div data-bbox="1552 1066 1807 1093"> Virtual 1:1 Partnering </div>
<div data-bbox="322 1182 551 1230">  </div> <div data-bbox="322 1257 551 1305">  </div> <div data-bbox="322 1337 551 1385">  </div> <div data-bbox="734 1182 954 1230">  </div> <div data-bbox="734 1257 875 1305">  </div> <div data-bbox="734 1337 925 1385">  </div>		

200+ confirmed speakers across event include:

Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
Nigel Sheail, Global Head of M&A and BD&L, Novartis
Brian Heaphy, SVP, Corporate Development, BMS
Nanna Lüneborg, General Partner, Forbion
Brad Robling VP Corporate Business Development, Eli Lilly
Debbie Harland, Venture Partner, SROne
Andrew Hack, Managing Director, Bain Capital Life Sciences
Sofia Ioannidou, Partner, Andera Partners
Stephanie Sirota, Partner and CBO, RTW Investments
Marta Helena Lesko, Head of BD Enabling Technologies, Merck KGaA
Markus Kalousek, Global Head Search & Evaluation, Novartis
Geraldine O'Keefe, Partner Public Equities, EQT Life Sciences
Catherine Isted, CFO, ReNeuron
Jasper Bos, General Partner, Forbion and CEO, Forbion European Acquisition
Lucas de Breed, Founder, August
Jean-Philippe Combal, CEO, Vivet Therapeutics
Elisa Petris, Partner, Syncona
Dick Sundh, VP, Head of Australia, Canada & Europe, Kite
Steve Hurly, CEO, Lava Therapeutics
Giuseppe Mazza, CEO, Engitix Therapeutics
Tej Panesar, Investment Director, Life Sciences, British Patient Capital
Diana Torgersen, Senior Associate, Novo Seeds
Edward van Wezel, Managing Partner, BGV
Roel Bulthuis, Managing Director, INKEF Capital
Mehdi Ainouche, Principal, Jeito
Alex Hamilton, Partner, Syncona
Jukka Muhonen, Global BD & Alliances, Orion Pharma
Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma
Steven Harris, Chairman, CS Pharmaceutical
Tim Luker, VP Venture Science, Corporate BD, Eli Lilly
Pierre-Louis Joffrin, CDO, Mogrify
Robin Bhattacharjee, CEO, Actimed
Bibhash Mukhopadhyay, Founding Partner, Sound BioVentures
Khatereh Ahmadi, Head of Search and Evaluation Team, European BD&L Hub, MSD
Guillaume Vignon, SVP BD, Beigene
Yuehua Cong, Executive Director, Head of Europe, Simcere Pharmaceutical Group
Maria Dahl, COO and Head of Europe, Innovent Bio

Don Xu, Managing Director, Lynx Capital
Anna Williamson, Executive Director, Roche Pharma Partnering
Bonnie Van Wilgenburg, Principal, Monograph Capital Partners
Michael Altorfer, CEO, Swiss Biotech Association
Viola Bronsema, CEO, BIO Deutschland
Anette Steenberg, CEO, Medicon Valley Alliance
Rebecca Pope (she/her), UK Digital & Data Science Innovation Lead, Roche UK
Peter Llewellyn-Davies, CEO, invIOs
Regina Hodits, Managing Partner, Wellington Partners
Erik van den Berg, CEO, AM Pharma
Renee Aguiar-Lucander, CEO, Calliditas Therapeutics
Ros Deegan, CEO, OMass Therapeutics
Valerie Vanhooren, CEO, ONA Therapeutics
João Siffert, CEO and President, Design Therapeutics
Suzanne Dilly, CEO, Valirx
Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience
Tara Raveendran, Head of Healthcare & Life Sciences Research, Polar Capital
Sofia Håkansson Buch, VP Cell Therapy CMC & Manufacturing, Novo Nordisk
Sven Kili, CEO, Antion
Jason Foster, CEO, Ori Biotech
Tom Shepherd, CEO, Captor Therapeutics
Bernd Boidol, CEO, Proxygen
Christian Dillon, CSO, Phoremest
Andrew Udell, President, North America, Calliditas Therapeutics
Maina Bhaman, Partner, Sofinnova Partners
Arthur Sands, CEO, Nurix
Marcel Zwaal, CEO, Gadeta
Klaas Zuideveld, CEO, Versameb
Steven Powell, CEO, eTheRNA immunotherapies
Nicklas Westerholm, CEO, Egetis Therapeutics
Fredrik Johansson, CFO, Calliditas Therapeutics
Steven Powell, CEO, eTheRNA immunotherapies
Anton Mat, Director of Business Development, ISA Pharmaceuticals
Michael Macpherson, Head Cyber Defence, Sensyne
John Dawson, Director, Oxford BioMedica
Michel de Baar, Executive Director BD&L, MSD
Marc Ramis Castelltort, Centure Partner, Chasing Science

Victoria Darbyshire, Equity Analyst, J.P. Morgan
 Eric Solis, Lead Data Scientist, Takeda
 David Crome, Managing Director Compliance UK, ProPharma Group
 Sally van Kooten, VP Commercial Strategy, KalVista
 Tahera Kan, VP Transactions, Johnson & Johnson Innovation EMEA
 Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates
 Alexandra Zemp, Partner, McKinsey
 Rachel Moss, Partner, McKinsey
 Cody Powers, Principal - Portfolio & Pipeline, ZS Associates
 Isabella Schidrich, Senior Managing Director, Nasdaq
 Mark Dorff, Partner, Brown Rudnick
 John Rudy, Member, Mintz
 Madeleine Armstrong, News Editor, Evaluate
 Pnina Weitz, Global Head Venture Capital BD & Relationship Management, Lonza
 Chris Rowe, Innovation Lead, Innovate UK
 Ed Saltzman, Executive Chairman, Humanity
 Beth Fordham-Meier, VP Business Development, Humanity
 Gwilym Attwell, Principal, Fish & Richardson
 Jim Polson, Managing Director, FTI Consulting
 Andrew Hill, Executive Director - Cyber Coverage Specialist, Willis Towers Watson
 Matt Cardinal, VP Strategy & Program Leadership, Halloran
 Johan Strömquist, CEO, NDA Group
 Björn Carlsson, Advisory Board Member, NDA Group
 Nick Pattinson, Head of Product, Automata
 Jan Kimpen, Chief Medical Officer, Philips
 Richard Cassidy, VP Rx+Global, Astellas Pharma
 Nazar Rasul, Global Head of Digital, Fresenius Kabi
 Gregoire Guillet, Chief Business & Value Officer – WeHealth Digital Medicine, Servier
 Mark Davies, Chief Medical Officer, IBM
 Susan Thomas, Clinical Director, Google Health UK
 Neil Jordan, Worldwide General Manager, Retail Health Innovation, Microsoft
 Caoimhe Vallely-Gilroy, Global Head of Digital Health & Therapeutics, Merck
 Gregg Talbert, SVP Head of Personalised Healthcare and Digital Partnering, Roche
 Mats Berggren, Head of Search & Evaluation, Digital Innovation and External R&D, Merck
 Anne-Kathrin Witt, Global Head Digital BD&L, Novartis
 Ethan Wergelis-Isaacson, Digital Health Strategy, Otsuka
 Eyal Zimlichman, Chief Medical Officer & Chief Innovation Officer, Sheba Medical Center
 Adam Landman, Chief Information and Digital Innovation Officer, Brigham Women's Hospital
 David Norton, Senior Lead Innovation Consultant, Royal Free London Foundation Trust
 Neil Gomes, System SVP for Digital & Human Experiences, Common Spirit Health

Sarah Yusuf, Consultant Radiologists & Group Director at Sandwell and West Birmingham NHS Trust
 Chris Robson, CEO, Living With
 Zach Henderson, Chief Commercial Officer, Glooko
 Robert Garber, Partner, 7WireVentures
 Christoph Kausch, Managing Partner, MTIP
 Steve Tolle, General Partner, HLM Venture Partners
 Rana Lonnen, Managing Director, dRx Capital, Novartis
 Assaf Barnea, CEO, Sanara Ventures
 Michael Niddam, Co-Founder & Managing Director, Kamet Ventures
 Ali Hasan, Chief Medical & Healthcare Officer, Vitality Health
 Dan Vahdat, CEO, Huma
 Arif Nathoo, CEO, Komodo Health
 Mike Alavarez, CEO, Qardio
 Alexander Chekan, Chief of Staff, Palta
 Madelyn Herzfeld, Founder & Vice Chairman, Carevive
 Fabian Scheugenpflug, Senior Ventures Associate, Plug and Play
 Sokratis Papafloratos, CEO, Numan
 Jessica McCreddie, Principal, Octopus Ventures
 Keren Leshem, CEO, Ocon Healthcare
 Lea Von Bidder, Co-Founder and President, Ava Health
 Neil Ward, VP EMEA, Pacific Biosciences
 Emma Stanton VP Clinical, Oxford Nanopore Technologies
 David Atkins, CEO, Congenica
 Kari Stefansson, CEO, deCODE Genetics
 Parker Moss, Chief Commercial Officer, Genomics England
 Daniel Neil, SVP AI, Benevolent AI
 Martin-Immanuel Bittner, CEO, Arctoris
 Neil Sahota, United Nations Artificial Intelligence Advisor and Interim CEO ACSILabs
 Cyndi Williams, CEO, Quin
 Paul Landau, CEO, Careology
 Caroline Noublanche, CEO, Apricity
 Tobias Silberzahn, Partner, McKinsey
 Bleddyn Rees, Chair, The Digital Health Society and Board Director ECHalliance
 Annemijn Eschauzier, Mentor and former CMO Women's Health, GE
 Marta Gaia Zanchi, Founder and Managing Partner, Nina Capital
 Hanno Ronte, Partner, Monitor Deloitte
 Rachel Ford Hutman, Founder and CEO, Ford Hutman Media
 Fiona Law, Partner, Potter Clarkson
 Lord David Prior, Chairman, NHS
 Wilfred Van Zuilen, President EMEA, Zimmer Biomet

Xavier Bertrand, VP Healthcare Services and Alliances, Boston Scientific
Charity Kufaas, VP BD and Strategy, Medtronic
Antonio Sanchez-Cordero, VP Business Development (M&A) Peripheral Intervention, BD
Rupert Winckler, Head of BD EMEA, Olympus
Thomas Hummel, Head of Strategy & Innovation, Siemens Healthineers
Markus Ott, VP and Head of Global Market Access and Health Policy, Roche Diagnostics
Angela Liedler, Managing Director, Precisis
Samih Al Mawass, Divisional Vice President EMEA Vascular, Abbott
Diana Saraceni, Managing Partner, Panakès Partners
Maarten Akkerman, Vice President Medical Affairs and Value-Based Healthcare, Medtronic
Frank Maddux, Global Chief Medical Officer, Fresenius Medical Care
Laura Niklason, CEO, Humacyte
Giles Hamilton, CEO, ODx Innovations
Gil Rabbie, Digital Solutions & Capability Development Leader, Boston Scientific
Per Vegard, CEO, CMR Surgical
Alain Chevallier, Senior Partner, Truffle Capital
Brian Hakim, Director of International Business Development, MedtecX
Baudouin Hue, Partner, Karista
Drew Burdon, Investment Manager, LSP
Modertor: Seamus Browne, Head of Industry Partnerships, Royal College of Surgeons
John E. Milad, CEO, Quanta

Sergio Levi, VP and Head of Strategic Alliances, Philips
Anne Osdoit, Partner, Sofinnova
Jose (Pepe) Callo Gordo, Managing Partner, Valiance
Georg Bortlein, Founder & President, High Life
Oliver Keown, Director, Intuitive Ventures
Luke Hares, CTO, CMR Surgical
Andreas Wuepper, Director Investments, Europe, Fresenius Medical Care Ventures
Lucy Mackillop, Chief Medical Officer, Sensyne Health
Marc Julien, Co-CEO, Diabeloop
Laurent Vandebrouck, CEO, Chronolife
Eliane Schutte, CEO, Xeltis
Ian Crosbie, CEO, Sequana Medical
Juliette Cook, Vice President Quality & Regulatory Affairs, Implantica
Claire Woodthorpe, COO and VP Europe, Lightpoint Medical
Graeme Smith, CEO, Lightpoint Medical
Carl Hewett Head of Medical Design Innovation, Sagentia Innovation
Gunnar Sachs, Partner, Clifford Chance
Robert Kieval, EVP Strategic Partnerships, Veranex
Ari Silverman, Partner, Mavie Technologies
Tina Amini, Medical Device Division Director, NDA Group
Linda Korthout, Director International Clinical Affairs, MCRA



Day 1 – Tuesday, 10 May – MAIN AGENDA

08.00	REGISTRATION & BREAKFAST
	BIOTECH LEADERS MORNING KEYNOTE PLENARY
09.00	WELCOME ADDRESS Josh Dance, SVP, LSX
09.05	KEYNOTE PRESENTATION: BIOTECH IN 2022: ANOTHER WAVE OR LOW TIDE? <ul style="list-style-type: none"> Review the 2021 biotech year in numbers: How much funding did the sector attract? How did the IPO market evolve? What are trends on the stock market? Deep-dive on external innovation: How do we see external innovation landscape evolve? What assets and companies are most successful? Looking ahead: What does this mean for 2022 and beyond? Alexandra Zemp, Partner, McKinsey (CONFIRMED) Rachel Moss, Partner, McKinsey (CONFIRMED)
09.30	KEYNOTE PANEL: THE NEXT PHASE OF EUROPE'S BOOMING BIOTECH ECOSYSTEM – BUILDING GLOBAL BIOTECH LEADERS, FINANCING NEXT WAVE INNOVATION AND JOINING THE DOTS BETWEEN CLUSTERS <i>After the shock in early 2020, the biotech ecosystem rebounded quickly and Europe was very much at the forefront of solving a the biggest global challenge in decades. As we enter the post-pandemic era, the European ecosystem has never been stronger with more capital, talent and experience and an ever-growing and more robust balance of early, growth and established companies. Executives of Europe's leading life biotech companies, investors and key stakeholders discuss the next phase, working in a pan-European collaborative strategy to translate innovation, and continue to strategically build an ever-stronger globally competitive powerhouse.</i> <ul style="list-style-type: none"> How and why has Europe survived and thrived? What are the next steps for continued sustainable growth of the whole ecosystem? Is access to talent and experience to drive companies becoming easier with the move to a more digital world with amounts of remote working? Accessing the US market and building a transatlantic footprint is still ever critical, but in what ways is Europe leading the way? With more capital in the space, both with larger private investment rounds and on the buoyant public markets, are companies able to build a longer-term vision? Has there been a cultural shift? Moderator: Mark Dorff, Partner, Brown Rudnick (CONFIRMED) Nanna Lüneborg, General Partner, Forbion (CONFIRMED) Brad Robling, VP, Lilly Ventures, Corporate BD, Eli Lilly (CONFIRMED) Debbie Harland, Venture Partner, SROne (CONFIRMED) Andrew Hack, Managing Director, Bain Capital Life Sciences (CONFIRMED) Werner Lanthaler, CEO, Evotec (CONFIRMED) Graziano Seghezzi, Managing Partner, Sofinnova (CONFIRMED)
10.30	MORNING BREAK

	CAPITAL MARKETS & INVESTMENT		PARTNERSHIPS & DEAL MAKING		CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY
11.00	<p>TRACK KEYNOTE PANEL: LEADING THE WAY IN THE GLOBAL INVESTMENT LANDSCAPE - NEW STRATEGIES, COMPETITION AND SYNDICATION</p> <p><i>The numbers paint a picture of a booming investment market but the how, where and why of this capital influx are nuanced. And while total deal values for European biotechs have increased, the increase in the US has been higher still, and US investors are increasingly participating and being a driver in larger investment rounds in European companies. The larger and more established funds continue to attract the largest pools for news funds and vehicles and are finding new ways to help their portfolio companies grow. Leading investors discuss the global investment landscape and the part being played by Europe's growth and maturation, as well as what they expect 2022 and onwards to hold.</i></p> <ul style="list-style-type: none"> • Is competition for deals higher than ever? • Could de-fragmented and re-invigorated European public markets help the maturing ecosystem further and compete with US public markets? • Evolution of funding vehicles and mandates – early stage, growth, crossovers, SPACs <p>Moderator: John Rudy, Member, Mintz (CONFIRMED) Sofia Ioannidou, Partner, Andera Partners (CONFIRMED) Stephanie Sirota, Partner and CBO, RTW Investments (CONFIRMED) Tej Panesar, Investment Director, Life Sciences, British Patient Capital (CONFIRMED) John Cassidy, Investment Director Life Sciences & HealthTech, Softbank Vision Fund (CONFIRMED)</p>	11.00	<p>TRACK KEYNOTE PANEL: THE NEW (AND IMPROVED) NORMAL - BUILDING A MORE CONNECTED EUROPEAN ECOSYSTEM</p> <p><i>After a period of enforced isolation, rather than a breakdown in communication many found efficiencies in the virtual world. As we get back to the 'new normal', how can Europe work to make this an improved normal, with a less fragmented and more collaborative ecosystem? Heads of leading life science hubs building cross-geography partnerships to build an even more robust European ecosystem.</i></p> <ul style="list-style-type: none"> • How are leading life science clusters working to build and develop and ensure success for innovators in their region? • Cultural, incentive and structural differences across the continent • Ideas and models for pan-European collaboration <p>Moderator: Madeleine Armstrong, News Editor, Evaluate (CONFIRMED) Bonnie Van Wilgenburg, Principal, Monograph Capital Partners (CONFIRMED) Michael Altorfer, CEO, Swiss Biotech Association (CONFIRMED) Viola Bronsema, CEO, BIO Deutschland (CONFIRMED) Anette Steenberg, CEO, Medicon Valley Alliance (CONFIRMED)</p>	11.00	<p>TRACK KEYNOTE PRESENTATION: THE FUTURE OF THE EMERGING BIOPHARMA LAUNCH LANDSCAPE</p> <ul style="list-style-type: none"> • Overview of the first-launch landscape - reviewing novel first launches in Europe and the US in the last decade • Best practices for first launches for COVID and beyond • Recent trends in launches with a spotlight on cell and gene therapy and oncology • What can we expect to see in the next 5 years in the emerging biopharma launch landscape? <p>Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates (CONFIRMED)</p>

11.45	<p>PRESENTATION: DE-RISK INVESTMENTS AND INCREASE ROI THROUGH STRATEGIC VC CDMO COLLABORATION <i>Early-stage investment in biotech is high risk due to the low probability of candidate success and increasing competition globally. Lonza has developed a unique business model to partner with VCs, supporting them in de-risking their investments by offering due diligence support and can increase ROI through proven, scalable development and manufacturing solutions for their product supply.</i></p> <ul style="list-style-type: none"> Partnering with a CDMO which takes a holistic approach to drug substance and drug product development How Portfolio companies can simplify their supply chain, resulting in a shortened development timeline Minimizing risks and reducing process complexity <p>Pnina Weitz, Global Head of Venture Capital Business Development & Relationship Management, Lonza (CONFIRMED)</p>	<p>11.45</p> <p>PRESENTATION: HOW AUTOMATION IS CHANGING THE WAY WE THINK ABOUT LABS Automation has long been a buzzword associated with leading edge science, but is usually resigned to specific assays & methods. However biotech R&D can be transformed by building automation across full laboratory workflows & integrating existing protocols. This session will explore key pillars of automation across laboratory environments to increase throughput, enhance data governance, and improve result comparability. It will also highlight key industries where automation is changing upstream processing for good.</p> <ul style="list-style-type: none"> Integrating existing workflows with automation platforms Unlocking comparable results without the hassle Baking in automation from the ground up <p>Nick Pattinson, Head of Product, Automata (CONFIRMED)</p>	<p>11.20</p> <p>PANEL: CHALLENGES AND OPERATIONAL SCALE UP FOR FIRST PRODUCT LAUNCH <i>Navigating the 'go-it-alone' strategy is a huge financial, operational, and structural undertaking. However, as the industry grows, evolves and matures, and with more capital in the space than ever before, first launches by emerging biopharma are becoming more commonplace - first launches have made up more than a quarter of all new molecules submitted to the FDA since 2016. Executives discuss...</i></p> <ul style="list-style-type: none"> What does it take to build, scale and prepare your company for launch? Exit valuations after commercialisation compared with a late stage partnering strategy Key success factors and considerations in a first launch and evolving into a commercial company <p>Moderator: Ben Hohn, Principal - Pharmaceuticals & Biotech, Emerging Pharma Lead, ZS Associates (CONFIRMED) Andrew Udell, President, North America, Calliditas Therapeutics (CONFIRMED) Sally van Kooten, VP Commercial Strategy, KalVista (CONFIRMED) Francis Pang, VP Global Market Access, Orchard Therapeutics (CONFIRMED)</p>
-------	--	--	--









12.05	<p>PANEL: STRIVING FOR PROGRESS IN DIVERSITY & INCLUSION</p> <p><i>Diversity is strength. Whether gender, ethnicity, or socio-economic background, in an industry that solves complex challenges it is the organisations and companies who have a variety of ideas, experiences, and mindsets that will be the most robust, resilient, and successful. Despite some improvements, there is a long way to go to in a truly equitable environment, and investment in terms of capital to more diverse organisations, but also time and focus is, needed to redress the imbalances. A multi-stakeholder panels discusses how the industry is faring, and what more of it should be doing, in championing Diversity, Equity and Inclusion (DEI).</i></p> <ul style="list-style-type: none"> • The key role of investors leading the way and providing equitable access to funding and resources • Prioritising DEI - practical steps investors, companies and the industry can take to make a difference • The importance of collecting data, considering metrics and taking learnings from them <p>Moderator: Ian Coyne, Executive Director Global Information & Intelligence, Coulter Partners (CONFIRMED) Priya Mande, CEO, PsiOxus Therapeutics (CONFIRMED) Rhoda Steel, Head of Community Impact, Johnson & Johnson UK (CONFIRMED)</p>	12.05	<p>PANEL: MOVING THE NEEDLE - SUCCESSFUL BUSINESS MODELS AT THE INTERFACE BETWEEN INDUSTRY, ACADEMIA AND INVESTMENT</p> <p><i>The pace of innovation in biotech and life sciences is only increasing and keeping at the cutting edge of new discoveries and next generation technologies is key. Pharma and investors are looking ever earlier to help support these ideas, alongside TTOs and accelerators, to translate early innovation into viable start-ups which can in turn then get treatments and technologies from the lab to the bedside as quickly as possible. A multi-stakeholder panel discusses evolving businesses models, stories of success, and how the whole ecosystem can work more effectively together.</i></p> <ul style="list-style-type: none"> • How to get new technology into commercially viable entities more quickly • Learning from the successes in the UK ecosystem and how these models can be implemented in other clusters • What more needs to be done to expedite translation of innovation? <p>Moderator: Marc Ramis Castelltort, Venture Partner, Chasing Science (CONFIRMED) Bill Haynes, Head of Novo Nordisk Research Centre Oxford, Novo Nordisk (CONFIRMED) Anne Horgan, Partner, Cambridge Innovation Capital (CONFIRMED) Dima Kuzmin, Managing Director, 4BIO Capital (CONFIRMED) Jason Mellad, CEO, Start Codon (CONFIRMED)</p>	12.05	<p>PANEL: BUSINESS MODELS FOR CELL & GENE THERAPY - EVOLUTION OR REVOLUTION FROM THE EXISTING BIOPHARMA MODEL?</p> <p><i>The advent, development and commercialization of new technologies entails the development and refinement of new business models that allows companies to create, deliver and capture value. Cell and Gene Therapy (CGT) is an exciting frontier in in therapeutics and capital investments are fuelling rapid scientific innovation and providing the opportunity for biotechs to commercialize themselves. However, there are several challenges associated with the CGT business models and some of these vary depending on the therapeutic modality and disease area being targeted. Industry leaders have long been talking about shifting from becoming a supplier of therapeutic products to delivering ‘value’ in the form of patient outcomes – CGT could be seen as a catalyst and accelerator of this change. But will this change require companies to evolve or create new business models?</i></p> <ul style="list-style-type: none"> • Which components of the biopharma business model are largely impacted by CGT? – value capture, value delivery or value creation • What does the future of CGT look like? • How does the system need to evolve for future commercial sustainability? • What are key capabilities that companies need to invest in to succeed in the future world? <p>Moderator: Maya Khurana, Health and Life Sciences Director, Oliver Wyman (CONFIRMED) Catherine Isted, CFO, ReNeuron (CONFIRMED) Lucas de Breed, Founder, August (CONFIRMED) Jean-Philippe Combal, CEO, Vivet Therapeutics (CONFIRMED) Elisa Petris, Partner, Syncona (CONFIRMED)</p>
12.45	LUNCH BREAK				

	CAPITAL MARKETS & INVESTMENT		PARTNERSHIPS & DEAL MAKING		CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY
13.45	<p>PANEL: SOURCING AND FUNDING NEXT GENERATION INNOVATION</p> <p><i>With more capital available for early-stage companies than ever before, how are investors sourcing the latest innovations with larger rounds, bigger and more diverse syndicates? What are their focus areas and how are they sourcing the latest discoveries and technological advances that will be the next wave of biotech leaders? As focus switches back from pandemic treatments and solutions, panel of early-stage investors discuss the early- landscape and what's exciting them in 2022.</i></p> <ul style="list-style-type: none"> Will we continue to see investors back the best companies with increasingly larger seed and series A funding rounds to give young companies a stronger runway? Geographical syndication – are early-stage investors seeing greater global interest in syndication opportunities? In the 'Golden Age of Biotechnology' we are in, which next generation tech is exciting investors? <p>Moderator: Chris Rowe, Innovation Lead, Innovate UK (CONFIRMED) Edward van Wezel, Managing Partner, BGV (CONFIRMED) Roel Bulthuis, Managing Director, INKEF Capital (CONFIRMED) Mehdi Ainouche, Principal, Jeito (CONFIRMED) Alex Hamilton, Partner, Syncona (CONFIRMED) Sara Secall, Partner, Inveready (CONFIRMED)</p>	13.45	<p>PANEL: MAKING A MARK - EMERGING PLAYERS IN BIOTECH DEALS AND AQUISITIONS</p> <p><i>While the world's largest pharma companies often dominate headlines with large 'biobucks' licencing agreements and M&A mega deals, a growing number of smaller pharma companies are also hungry for partnerships, deals and acquisitions. Heads of BD & M&A and emerging deal-makers at growing pharma share their strategies, focus areas and how they are looking to make their mark in the biopharma landscape.</i></p> <ul style="list-style-type: none"> Finding the right partners and in dedicated ecosystems Smaller biopharma's partnering and deal making strategies in a competitive market Strategic alignment - key therapeutic areas of interest <p>Moderator: Guy Martin, Deputy Editor, Pharma Letter (CONFIRMED) Jukka Muhonen, Global BD & Alliances, Orion Pharma (CONFIRMED) Kieran Rooney, VP, Strategic Alliances and Licensing, Amryt Pharma (CONFIRMED) Steven Harris, Chairman, CS Pharmaceuticals (CONFIRMED)</p>	13.45	<p>PANEL: A PLATFORM FOR SUCCESS – STRATEGIC IMPERATIVES IN BUILDING AND GROWING DISCOVERY PLATFORMS</p> <p><i>After two decades of venture investors primarily funding product-centric companies, now newly hatched companies with disruptive drug discovery platforms but no identified lead assets are raising historically unprecedented financings. Platform companies face numerous strategic development challenges prior to and beyond the point at which the value of tangible product assets ultimately takes over as the principal valuation driver. The rewards of developing a compelling corporate development strategy can be considerable, since strategically developed platforms are capable of generating enterprise value both more rapidly and expansively than conventional "phase transition" asset development. Early-stage investors and platform company CEOs discuss the strategic imperatives in extracting optimal near and long-term value from discovery platforms.</i></p> <ul style="list-style-type: none"> Determining and executing near-term preclinical studies Selecting and prioritising therapeutic area(s), disease(s) and indication(s) Taking a portfolio approach to platform vs target risk Developing a proactive strategy to utilize partnering as a strategic value multiplier <p>Moderator: Ed Saltzman, Head Biotech Strategy, Lumanity (CONFIRMED) Giuseppe Mazza, CEO, Engitix Therapeutics (CONFIRMED) Maina Bhaman, Partner, Sofinnova Partners (CONFIRMED) Arthur Sands, CEO, Nurix (CONFIRMED) Klaas Zuideveld, CEO, Versameb (CONFIRMED)</p>

14.30	<p>PANEL: PREPARING FOR AND PROTECTING YOUR ASSETS WHEN ENTERING THE US</p> <p><i>Entering the US market can be a challenge, but it is becoming a strategic consideration ever-earlier in the growth process for many companies. Asset protection when entering a new market is the key to long-term success and includes securing capital from investors, preparing for licensing and transactions, and minimizing litigation risk. Efficient and effective due diligence can protect your assets and save you time, money and headaches further down the line. A multi-stakeholder panel will discuss how companies and their investors can optimize their intellectual property portfolios for entry to the US.</i></p> <ul style="list-style-type: none">• How investors analyse, identify and mitigate risk in investing in life science companies seeking to market in the US• How to put yourself in the best possible position for investment and deals• What assets investors and partners will want to see in your intellectual property portfolio• How to protect privileged and confidential information during the due diligence process <p>Moderator: Gwilym Attwell, Principal, Fish & Richardson (CONFIRMED) Tim Luker, VP Venture Science, Corporate BD, Eli Lilly (CONFIRMED) Pierre-Louis Joffrin, CDO, Mogrify (CONFIRMED) Robin Bhattacharjee, CEO, Actimed (CONFIRMED)</p>	14.30	<p>PANEL: COMPETITION INTENSIFYING? CHINA’S PARTNERING AND DEAL MAKING STRATEGIES</p> <p><i>Records levels of cross-border licensing partnerships have been agreed between multi-national Pharma and Chinese companies through 2020 and 2021. Deals boomed both for Pharma acquiring or partnering on innovative Chinese assets as well as Chinese companies developing and commercialising drugs for Western companies. While capital is still awash in China, this increased activity has meant a more competitive landscape - has sourcing and building win-win deals become ever harder? Executives discuss the booming Chinese partnering and deal-making landscape.</i></p> <ul style="list-style-type: none">• Will the growth in cross-border transactions with Chinese companies continue?• In a more global competitive market for deals, how are strategies evolving?• What are Chinese companies looking for in deals? <p>Moderator Hayley French, Investor, Vesalius Biocapital Partners (CONFIRMED) Yuehua Cong, Executive Director, Head of Europe, Simcere Pharmaceutical Group (CONFIRMED) Maria Dahl, COO and Head of Europe, Innovent Bio (CONFIRMED) Don Xu, Managing Director, Lynx Capital (CONFIRMED)</p>	14.30	<p>PANEL: KEY MULTI-STAKEHOLDER CONSIDERATIONS IN EARLY-STAGE COMMERCIAL DEAL-MAKING</p> <p>Early-stage deal-making is an important strategy for innovators to obtain external expert validation, expand capabilities, advance program(s), and secure “nondilutive” financing. But early-stage deals can detract value and optionality for the innovator if not thoughtfully pursued and negotiated. While an interested large pharma licensor may have hope the innovator’s technology or asset will lead to successfully marketed product(s), there will be pressure to off-load risk and responsibility and minimize the innovator’s share of deal value until later milestones are achieved. Increasingly innovator licensors are retaining responsibility for advancing the licensed programs through pre- and clinical development before future payments and licensee’s responsibilities kick in. While increasing “upfront” and “biobucks”, this can essentially become an option-based co-development deal requiring the innovator to invest much of that upfront payment. Is the “juice” of these deals worth the “squeeze”? Is the deal truly validating if the licensor isn’t all-in at deal signing? Is this risk- and cost-sharing by the innovator rewarded through future milestones and royalties or just a required toll to get an early-stage deal done?</p> <ul style="list-style-type: none">• Are early-stage deals essential to validate pipeline and secure investment? How is raising capital balanced with deal-making?• What have early-stage partnerships enabled, what hurdles have been faced, and what does it take to make deals work long-term?• What advice or requests would biotech have for large pharma for early-stage deal-making?• What advice for successful early-stage deal-making would large pharma give biotech beyond “come back when you have more data”?• What are strategies for achieving a “fair deal”? <p>Moderator: Beth Fordham-Meier, VP Business Development Commercial BioConsulting, Lumanity (CONFIRMED) Khatereh Ahmadi, Head of S&E Team, MSD (CONFIRMED) Steven Powell, CEO, eTheRNA immunotherapies (CONFIRMED) Anton Mat, Director BD, ISA Pharmaceuticals (CONFIRMED) Sarah Holland, Chief Business Officer, VectivBio (invited)</p>
15.15	AFTERNOON BREAK				

	BIOTECH LEADERS AFTERNOON KEYNOTE PLENARY
16.00	<p>AFTERNOON KEYNOTE PANEL: REBOUNDED, REBUILDING, REIMAGINED – PHARMA BD & M&A OUTLOOK IN 2022 AND BEYOND</p> <p><i>Whilst somewhat dampened through 2020, there are predictions of extensive M&A activity through 2021 and in 2022 as beyond as in-person deal-making returns and the industry rebounds. Both ‘mega-mergers’ and smaller bolt on deals to supplement pipelines and get cutting edge innovations to patients faster are slated, though with a backdrop of increased scrutiny of larger deals and an increasing diversity in innovation across the healthcare sector. Are Pharma’s strategies evolving and can we expect an increasingly active market? Leading global deal-makers discuss how M&A activity will evolve in the biopharma industry.</i></p> <ul style="list-style-type: none"> • With competition authorities increasingly looking at complex M&A activity, what kind of difference could this make to the pharma industry? • Will smaller bolt-on acquisitions continue as a key engine for driving growth? • Will oncology continue to dominate deal-making? Which other new technology innovations are the world’s largest companies looking at with most interest? <p>Moderator: Robbie McLaren, Partner and Vice Chair of the Global Life Sciences Practice, Latham & Watkins (CONFIRMED) Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA (CONFIRMED) Nigel Sheail, Global Head of M&A and BD&L, Novartis (CONFIRMED) Brian Heaphy, SVP, Corporate Development, BMS (CONFIRMED)</p>
16.45	<p>FIRESIDE CHAT: THE GROWING ROLE OF MACHINE LEARNING IN RARE DISEASE</p> <p><i>A constellation of missed clinical signals contribute to the diagnostic odyssey facing rare disease patients. Patterns in clinical presentation are often misinterpreted, creating a challenging data science problem. Cutting edge predictive machine learning models are generating powerful results – understand how in this fireside chat discussion with Horizon Therapeutics and Komodo Health.</i></p> <p>Moderator: Tina Tan, Executive Editor, FirstWord HealthTech (CONFIRMED) Arif Nathoo, Co-Founder and CEO, Komodo Health (CONFIRMED) Igor Rudychyev, VP Enterprise Analytics, Horizon Therapeutics (CONFIRMED)</p>
17.05	<p>CLOSING KEYNOTE PANEL: INTRODUCING ‘OUR FUTURE HEALTH’</p> <p><i>Our Future Health is an ambitious collaboration between the public, charity and private sectors that will be the UK’s largest ever health research programme. The initiative will provide a world-leading resource for health researchers comprising a prospective observational dataset of 5M participants from across the UK combined with a powerful translational research platform. Researchers from around the world will be able to use the resource to discover and test more effective ways to predict, prevent, detect and treat diseases. Backed by more than £100M from life science companies, £79M from Innovate UK and £55M aligned to the Genome UK Strategy, Our Future Health is backed is also endorsed by numerous medical research charities. Key members of the collaboration will provide an overview of Our Future Health, with perspectives from both founding industry and charity members, and will highlight opportunities to get involved and utilise this new and exciting resource.</i></p> <p>Moderator: Anna Williamson, Executive Director, Roche Pharma Partnering (She/her) (CONFIRMED) Andrew Roddam, CEO, Our Future Health (He/him) (CONFIRMED) Rebecca Pope, UK Digital & Data Science Innovation Lead, Roche Products (She/her) (CONFIRMED) Wen Hwa Lee, CEO and Chief Scientist, Action Against AMD (He/him) (CONFIRMED) Chris Chamberlain, Executive Director Experimental Medicine, AstraZeneca (CONFIRMED)</p>
17.45	CLOSE OF DAY 1 AGENDA – DRINKS RECEPTION
18.30	SEARCYS @ THE GHERKIN NETWORKING PARTY

Day 1 – Tuesday, 10 May – SATELLITE SESSIONS

08.00	REGISTRATION & BREAKFAST		
09.00	KEYNOTE SESSIONS		
10.30	MORNING BREAK		
10.30	Biotech Showcase Integrate 1 - On Floor	Medtech & Healthtech Showcase Integrate 1 - On Floor	CEO Forums Integrate 2 and 3
	9 x Company Presentations	9 x Company Presentations	 <p>Co-hosted by:</p>  
12.45	LUNCH BREAK		
13.45	9 x Company Presentations	9 x Company Presentations	 <p>Co-hosted by:</p>  
16.00	7 x Company Presentations	7 x Company Presentations	 <p>Co-hosted by:</p> 
17.45	NETWORKING DRINKS		



Day 2 – Wednesday, 11 May – MAIN AGENDA

08.00	REGISTRATION & BREAKFAST
	BIOTECH LEADERS MORNING KEYNOTE PLENARY
09.25	WELCOME ADDRESS Josh Dance, SVP, LSX
09.30	KEYNOTE PANEL: GO WEST! – CONSIDERATIONS FOR US IPOs AND DUAL LISTINGS <i>After a record-breaking year in 2020, the IPO market has slowed in 2021. For European companies, what remains is the stark contrast in terms of listings on local European exchanges compared to what is now a well-trodden route to Nasdaq. The huge amount of capital available in the US has long provided a pull for European biotechs and with healthcare in general brought to the fore more than ever before in 2020, many companies took advantage of the open IPO window to list or dual-list in the US. A major consideration for any company, executives who have taken their businesses public in the US discuss the decision and timing their listing, how they managed during in a period of huge disruption and travel restrictions and key success factors in taking European companies to Nasdaq.</i> <ul style="list-style-type: none"> • Key considerations for companies looking to tap the US public markets • What skills and experience are necessary to bring on to your board and management team for life on US public markets? • The European discount – is perception of European companies being undervalued (or US companies overvalued) a reality? • Has the biotech IPO market peaked? Is the window closing? <p>Moderator: Isabella Schidrich, Senior Managing Director, Nasdaq (CONFIRMED) Steve Hurly, CEO, Lava Therapeutics (CONFIRMED) Pierluigi Paracchi, CEO & Co-founder, Genenta Science (CONFIRMED) Piers Morgan, CFO, CellCentric (CONFIRMED) Fredrik Johansson, CFO, Calliditas Therapeutics (CONFIRMED)</p>
10.30	MORNING BREAK

	CAPITAL MARKETS & INVESTMENT		PARTNERSHIPS & DEAL MAKING		CAPITAL DEPLOYMENT & COMMERCIALISATION STRATEGY
11.00	<p>PANEL: SPACS – ARE THEY HERE TO STAY AND HOW WILL THEY EVOLVE?</p> <p><i>Whilst blank cheques are not a new vehicle, SPACs in biotech and healthcare have exploded and been the hottest trend in the sector. There is much debate around the pros and cons, with SPACs allowing the ability to merge crossover rounds with the IPO into one step and giving speed to market for the companies, but many, including at Pharma, have reservations. Are SPACs here to stay in the life science industry for the long term? Experts and SPAC sponsors discuss the recent boom, the future of the vehicles in the space and how the products could evolve moving forward</i></p> <ul style="list-style-type: none"> • What are the pros and cons for companies considering a SPAC compared to a traditional IPO? • What makes a company attractive for a de-SPAC merger? • Are these vehicles, which have exploded in the US, to become increasingly commonplace in Europe? <p>Moderator: Jim Polson, Managing Director, FTI Consulting (CONFIRMED) Jasper Bos, General Partner, Forbion and CEO, Forbion European Acquisition (CONFIRMED)</p>	11.00	<p>TRACK KEYNOTE PRESENTATION AND PANEL: GO-TO-MARKET STRATEGIES ACROSS GEOGRAPHIES AND OVERALL EQUITY RETURNS</p> <p><i>Biotech companies' commercial planning should be starting earlier and earlier as industry dynamics shift. A key consideration will be the strategy around commercialising in different geographies and potential partnerships in licencing or co-promotion. But how do these decision affect overall equity returns? After a presentation of in-depth analysis to date, executives and investors discuss:</i></p> <ul style="list-style-type: none"> • Developing a global commercial strategy and considerations for commercialisation rights • Going alone or licencing or co-promoting across different geographies and how that impacts overall equity value • Analysing the importance of retention of commercialisation rights in different geographies • Investor perspectives on biotech's commercial strategies <p>Presenter and moderator: Cody Powers, Principal - Portfolio & Pipeline, ZS Associates (CONFIRMED) Peter Llewellyn-Davies, CEO, invIOs (CONFIRMED) Regina Hodits, Managing Partner, Wellington Partners (CONFIRMED) Erik van den Berg, CEO, AM Pharma (CONFIRMED) Renee Aguiar-Lucander, CEO, Calliditas Therapeutics (CONFIRMED)</p>	11.00	<p>TRACK KEYNOTE PANEL: MANAGING RISK IN THE NEW WORLD – SECURITY, DATA, RESILIENCE IN THE BIOPHARMA SUPPLY CHAIN</p> <p><i>The last 24 months have been quite historic for organisations within the life sciences and healthcare industries. In addition to the obvious global COVID-19 response, businesses have continued to grow and evolve in cyber terms. Whether it be innovations in cyber-enabled treatments or therapies, or making the best use of technology to support efficient delivery of organisational objectives and business strategies, one thing is clear – the industry is at the very forefront of the cyber operating environment. With this level of innovation, the heightened degree of interaction within the cyber space, and in considering the 'data heavy' and highly regulated nature of the industry, all against a backdrop of growing and emerging cyber threats, it is crucial that life science and healthcare organisations of all types view cyber risk as being amongst, if not the, biggest risks to their businesses.</i></p> <ul style="list-style-type: none"> • What does the cyber threat landscape look like for this industry? • Have cyber security practices kept pace with innovation and the implementation of new technologies? • Is the convergence of the physical and virtual domains fully understood by this industry, and what are the risks in this space? • How can organisations better protect themselves in the now, and what or where should they focus their efforts in looking ahead? <p>Moderator: Andrew Hill, Executive Director - Cyber Coverage Specialist, WTW (CONFIRMED) David Crome, Managing Director Compliance UK, ProPharma Group (CONFIRMED) Simon Basham, Head of Cyber & TMT Broking UK, WTW (CONFIRMED)</p>

11.20	<p>PANEL: WHAT'S NEXT NOW THE MUSIC HAS STOPPED? - ASSESSING THE VOLATILE PUBLIC MARKETS</p> <p><i>The pandemic-caused global recession passed biotech by in 2020 and 2021, with investment and funding reaching record levels including an explosion of IPOs, SPACs and follow-ons. 2022 so far has been a different story with the S&P index of biotech stocks down significantly alongside more macro issues of economic recovery from the pandemic and major macro-economic and geopolitical uncertainties. The question now becomes, what next for the public markets and is the current environment sustainable? Fund managers and analysts debate the future of the capital markets.</i></p> <ul style="list-style-type: none"> • Was biotech due this correction and to this extent? • The impact and risks of the deep-pocketed new entrants to healthcare investment and their long-term stickability • What are the reasons for optimism, and what are the ongoing risks and challenges? • What could the future look like for the next generation of drug developers? <p>Moderator: Lala Gregorek, Healthcare Analyst, Trinity Delta (CONFIRMED) Ulrica Slåne Bjerke, CIO, Arctic Aurora LifeScience (CONFIRMED) Tara Raveendran, Head of Healthcare & Life Sciences Research, Polar Capital (CONFIRMED) Victoria Darbyshire, Equity Analyst, J.P. Morgan (CONFIRMED)</p>	12.00	<p>PRESENTATION: SUCCESSFUL PARTNERSHIPS WHEN OUTSOURCING – KEY CONSIDERATIONS AND DELIVERING BUSINESS VALUE</p> <p>Selecting the right outsourcing partners is critical to growing biotechs, and no area more so than with laboratory services. This session will highlight some of the key considerations when selecting an outsource partner as well as the potential business value that can be gained through effective partnerships</p> <ul style="list-style-type: none"> • Regulatory acceptance • Depth v Breadth of service and Experience v Expertise • Global or local? • 3rd party co-operation <p>Jette Cowan, Head Of Commercial – Pharmaceuticals, RSSL (CONFIRMED)</p>	11.40	<p>PANEL: DRESSING FOR SUCCESS EARLY AS A BIOPHARMA STARTUP</p> <p><i>Pre-Clinical biopharma start-ups often don't have time to rest – always needing to propel their organization to their next phase of development. But what that next phase of development looks like uniquely to that organization is often unclear and when do they need to 'dress' for it are common questions. Identifying the structural, technical, and development challenges to plan for in trying to get to the next level are widely complex. A panel of executives from growing biotechs discuss how they managed, or are managing though, the realities they have faced as a start-up.</i></p> <ul style="list-style-type: none"> • Working strategically through the planning process – what to do and when? • Key success factors in setting yourself up for the next phase of growth • The challenges of building and growing a startup and how to manage and overcome them <p>Moderator: Matt Cardinal, VP Strategy & Program Leadership, Halloran (CONFIRMED) Ros Deegan, CEO, OMass Therapeutics (CONFIRMED) Valerie Vanhooren, CEO, ONA Therapeutics (CONFIRMED) João Siffert, CEO and President, Design Therapeutics (CONFIRMED) Suzanne Dilly, CEO, Valirx (CONFIRMED)</p>
-------	--	-------	--	-------	---

		<p>12.20</p> <p>PANEL: FINDING THE FIT - WIN-WIN DEALS IN PHARMA PARTNERING</p> <p><i>As the pace of innovation across the healthcare space increases, pharma are ever-more active in scouting for early and later stage deals. The expertise, resources and connections of industry giants remains critical, but in a sector awash with capital and with increased competition, are strategies changing? Pharma S&E and BD executives discuss how they are supporting innovation, going earlier in building their pipelines, and the increasingly competitive landscape for attractive deals.</i></p> <ul style="list-style-type: none"> • "Earlier and earlier" cried Alice in Pharmaland - how are the industry biggest players looking to source innovation sooner and support the youngest startups? • Is it more competitive than ever before? • What are the key considerations for companies in their partnering strategy approaching pharma, and are most commonly overlooked? • Which type of partnering at which stage? <p>Moderator: Stephanie Léouzon, Partner, Torrey (CONFIRMED) Tim Luker, VP Venture Science, Corporate BD, Eli Lilly (CONFIRMED) Marta Helena Lesko, Head of BD Enabling Technologies, Merck KGaA (CONFIRMED) Markus Kalousek, Global Head Search & Evaluation, Novartis (CONFIRMED) Tahera Kan, VP Transactions, Johnson & Johnson Innovation EMEA (CONFIRMED)</p>	<p>12.20</p> <p>PANEL: MULTI-JURISDICTIONAL DRUG DEVELOPMENT</p> <p><i>The pandemic had ripple effects throughout the healthcare industry, one of which being regulatory healthcare authorities undergoing their own adaptation and changes. A lot more communication between regulators in different geographies is now more common, with a lot more sharing of information. Experts and companies who undertaking and multi-jurisdictional drug development discuss what this mean for companies and the wider industry post-covid.</i></p> <ul style="list-style-type: none"> • Navigating drug development strategy across the FDA, EMA, MHRA and other regulatory bodies • Key success factors in targeting multiple jurisdictions at the same time • Starting early and with the end in mind whilst avoiding common pitfalls and bottlenecks <p>Moderator: Johan Strömquist, CEO, NDA. Group (CONFIRMED) Björn Carlsson, Principal Consultant and Advisory Board Member, NDA Group (CONFIRMED) Nicklas Westerholm, CEO, Egetis Therapeutics (CONFIRMED) Tim Morris, COO and CFO, Humanigen (CONFIRMED)</p>
13.00	LUNCH BREAK		

14.00 FIRESIDE CHAT: REALISING OPPORTUNITIES AND POTENTIAL IN CELL THERAPY

- Novo Nordisk's work in cell therapy and therapeutic areas being expanding into
- Manufacturing capabilities have and US manufacturing expansion - considerations of build vs buy
- Ambitions within cell therapy in the coming years

Sofia Håkansson Buch, VP Cell Therapy CMC, Novo Nordisk (CONFIRMED)

Moderator: Franc Gregori, Analyst, Trinity Delta (CONFIRMED)

14.20 AFTERNOON KEYNOTE PANEL: SHAPING THE FUTURE OF ADVANCED THERAPIES - TIME TO DELIVER AND REALISE FULL VALUE?

The promise and hype of advanced therapies is finally translating into a reality and represents the next major wave of therapeutics. With mRNA vaccines playing a lead role in the fight against COVID-19 providing further optimism and validation, Pharma and biotech have burgeoning pre-clinical and clinical pipelines across various therapeutic areas - over 60 C> products have been approved worldwide and there are around 2,000 open or planned clinical trials. With huge increases in investment and M&A activity in the space, the future of cell and gene therapies is bright, but many challenges remain – what is the future of advanced therapies, and how are companies working to expedite getting this technology from bench to bedside?

- While oncology still dominates, which other therapeutic areas are showing promise?
- Clinical challenges - limited sites performing perform C> trials effectively, patient recruitment and long-term follow-up
- Manufacturing challenges - time, labour intensive and expensive processes, supply chain risks, achieving commercial scale
- Reimbursement and commercialisation challenges - high costs and proving value, obtaining reimbursement across geographies, public misinformation

Moderator: Lala Gregorek, Healthcare Analyst, Trinity Delta (CONFIRMED)

Sofia Håkansson Buch, VP Cell Therapy CMC, Novo Nordisk (CONFIRMED)

Sven Kili, CEO, Antion (CONFIRMED)

Jason Foster, CEO, Ori Biotech (CONFIRMED)

Marcel Zwaal, CEO, Gadeta (CONFIRMED)

John Dawson, Director, Oxford BioMedica (CONFIRMED)

15.10 CLOSING SPOTLIGHT PANEL: MAKING THE UNDRUGGABLE, DRUGGABLE - THE EXCITING POTENTIAL OF TARGETTED PROTEIN DEGRADATION

The concept of targeted protein degradation presents revolutionary drug development opportunities and, similar to technology innovations which have come before like gene-editing, is anticipated to bring about a paradigm shift in modern healthcare in the coming years. As the TPD field grows, with increased investment and more Pharma programmes, new companies emerging with new approaches and assets entering the clinic, executives discuss this new frontier of medicine, and what is needed to realise its full potential.

- What are the limitations of existing TPD approaches, and what could the next generation look like?
- Do TPD drugs have the potential to be the next blockbusters?
- What are the key challenges in the TPD field? Which key factors that are likely to influence the evolution of the area?

Moderator: Lisa Melton, Senior News Editor, Nature Biotechnology (CONFIRMED)

Tom Shepherd, CEO, Captor Therapeutics (CONFIRMED)

Bernd Boidol, CEO, Proxygen (CONFIRMED)







Christian Dillon, CSO, Phoremest (CONFIRMED)

Nicki Thompson, CEO, Amphista Therapeutics (CONFIRMED)

Michel de Baar, Executive Director BD&L, MSD (CONFIRMED)

16.00 CLOSE OF CONGRESS

Day 2 – Wednesday, 11 May – SATELLITE SESSIONS

08.00	REGISTRATION & BREAKFAST			
09.00	KEYNOTE SESSIONS			
10.30	MORNING BREAK			
11.00	Biotech Showcase Integrate 1 - On Floor	Medtech & Healthtech Showcase Integrate 1 - On Floor	CEO Forums Integrate 2	Workshops Integrate 3
	8 x Company Presentatons	8 x Company Presentations	<div> Co-hosted by: </div>	<div> Co-hosted by: </div>
13.00	LUNCH BREAK			
14.00	7 x Company Presentations	7 x Company Presentations	<div> Co-hosted by: </div>	
16.00	CLOSE			